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Cell-based therapy has emerged as a promising therapy for cardiovascular disease. Particularly, bone marrow (BM)-derived
cells have been most extensively investigated and have shown encouraging results in preclinical studies. Clinical trials,
however, have demonstrated split results in post-myocardial infarction cardiac repair. Mechanistically, transdifferentiation of
BM-derived cells into cardiovascular tissue demonstrated by earlier studies is now known to play a minor role in functional
recovery, and humoral and paracrine effects turned out to be main mechanisms responsible for tissue regeneration and
functional recovery. With this advancement in the mechanistic insight of BM-derived cells, new efforts have been made to
identify cell population, which can be readily isolated and obtained in sufficient quantity without mobilization and have
higher therapeutic potential. Recently, haematopoietic CD31+ cells, which are more prevalent in bone marrow and peripheral
blood, have been revealed to have angiogenic and vasculogenic activities and strong potential for therapeutic
neovascularization in ischaemic tissues. This article will cover the recent advances in BM-derived cell-based therapy and
implication of CD31+ cells.
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cell; ESC, embryonic stem cell; GATA2, GATA binding protein-2; G-CSF, granulocyte-colony stimulating factor; GM-CSF,
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Introduction
Ischaemic cardiovascular disease is the leading cause of death
in the United States (Roger et al., 2010). There are many
pharmacological and surgical therapies commonly used to
treat patients with cardiovascular diseases. However, a major-
ity of patients show deteriorated symptoms, progressive heart
failure and increasing need for hospitalization (Fang et al.,
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2008; Murry and Keller, 2008). Moreover, limited available
therapies and need for multiple treatments are problems for
tackling peripheral vascular disease (Taylor et al., 2007; Fein-
glass et al., 2009) in addition to the risk of amputation. There-
fore, there has been increasing demand for new therapies for
ischaemic cardiovascular diseases. The main cause of these
diseases is atherosclerosis which leads to blocking of the
blood vessels. Once vessels are blocked, new vascular growth
is required to rescue the endangered target tissues. As
endothelial cells (ECs) are a major component of blood
vessels and a leading component of vascular growth, thera-
pies for treating ischaemic cardiovascular diseases should
target regeneration of ECs.
Stem cells have drawn people’s attention over the past
decade due to their potential for new tissue generation.
Embryonic stem cells (ESCs) have a strong regenerative
potential and thus have been widely studied for cardiovascu-
lar regeneration in animal models. However, the risks of ter-
atoma formation (Cao et al., 2006) and host immune
response to allogeneic ESCs (Bifari et al., 2010) as well as
ethical concerns need to be solved for clinical translation.
The recent discovery of induced pluripotent stem cells (Taka-
hashi and Yamanaka, 2006; Takahashi et al., 2007) offered
new hope to circumvent ethical and immunologic concerns
associated with ESCs. However, many questions still remain
in regard to their therapeutic effects and adverse effects
(Hacein-Bey-Abina et al., 2003; Dhodapkar et al., 2010; Hu
et al., 2010; Kim et al., 2010b; Polo et al., 2010; Zhao et al.,
2011).
Although seemingly not as potent as ESCs, adult stem or
progenitor cells opened the cell therapy era for treating car-
diovascular diseases. Among many types of adult stem or
progenitor cells, bone marrow (BM)-derived cells have been
most widely investigated and shown tissue regenerative
effects in preclinical studies as well as some clinical trials.
Particularly, BM-derived endothelial progenitor cells (EPCs)
have been studied by many research groups and have shown
therapeutic potentials in animal models of myocardial and
peripheral vascular ischaemia (Kalka et al., 2000; Murohara
et al., 2000; Schatteman et al., 2000; Kawamoto et al., 2001;
2006; Kocher et al., 2001; Iwasaki et al., 2006; Jeong et al.,
2009). Moreover, a series of clinical trials using EPCs or
similar BM cells has shown therapeutic benefits to treat post-
myocardial infarction (MI) cardiac dysfunction and critical
limb ischaemia (Assmus et al., 2002; 2006; Bartunek et al.,
2005; Boyle et al., 2006; Schaefer et al., 2006; Li et al., 2007;
Losordo et al., 2007; 2011; Stamm et al., 2007; Tatsumi et al.,
2007; Hare et al., 2009; Burt et al., 2010; Kuroda et al., 2011;
Miettinen et al., 2010). On the other hand, other studies have
revealed conflicting results with regard to the effects of
BM-derived mononuclear cells (MNCs) on myocardial ischae-
mia in a similar subset of patients (Janssens et al., 2006;
Lunde et al., 2006; Meyer et al., 2006; Penicka et al., 2007). As
there are larger clinical trials with MNCs, early EPCs or CD34+
cells are under way, and more agreeable conclusion will be
drawn in the near future. In addition, there have been new
advances in the understanding of mechanisms governing
therapeutic effects of BM-derived stem and progenitor cells.
Earlier studies demonstrated that transdifferentiation into
vasculature and cardiomyocytes is the dominant mechanism
responsible for cardiac regeneration or repair (Asahara et al.,
1999; Jackson et al., 2001; Kocher et al., 2001; Orlic et al.,
2001; Murayama et al., 2002; Yeh et al., 2003; Ii et al., 2005;
Bauer et al., 2006; Iwakura et al., 2006; Iwasaki et al., 2006;
Kawamoto et al., 2006; Masuda et al., 2007). However, later
studies have uncovered that this transdifferentiation poten-
tial was overestimated (Balsam et al., 2004; Murry et al., 2004;
Ziegelhoeffer et al., 2004) and humoral or paracrine effects are
the main mechanism underlying therapeutic potential of
BM-derived cells. These humoral mechanisms, by protecting
ongoing cell apoptosis and degeneration, inducing neovascu-
larization, and promoting regeneration of endothelial cells,
cardiomyocytes and smooth muscle cells through soluble
factors or cell-to-cell contact (Rehman et al., 2003; Kinnaird
et al., 2004; Gnecchi et al., 2005; Ii et al., 2005; Urbich et al.,
2005; Yoon et al., 2005b; Uemura et al., 2006; Cho et al.,
2007; Miyamoto et al., 2007; Dai et al., 2008), can benefit
regeneration and repair of myocardium or peripheral vascular
tissues. There have been attempts to identify soluble factors
responsible for paracrine effects of mesenchymal stem cells
(MSCs), which led to the identification of secreted frizzled
related protein 2 (Sfrp2), an antagonist of the Wnt signalling
(Mirotsou et al., 2007). In this study, Sfrp2 was shown to have
dose-dependent cytoprotective effects with concentration of
up to 15 nM in in vitro caspase activity assay. In addition, a
follow-up study demonstrated that exogenous delivery of
Sfrp2 to rat hearts at a therapeutic dose of 4 mg per heart
improved cardiac function in experimental MI (He et al.,
2010).
Based on this new discovery on mechanisms of
BM-derived cells, there have been efforts to identify ‘effector’
cells based on markers that are not specifically restricted to
stem or progenitor cells and to utilize such cells for therapeu-
tic neovascularization (Hur et al., 2007; Kim et al., 2010a,c).
In fact, a subpopulation of BM- and peripheral blood (PB)-
derived MNCs expressing CD31 on the surface was shown to
have higher angiogenic and vasculogenic activities and exert
efficient neovascularization in hindlimb ischaemia (Kim
et al., 2010a,c). Hence, this review will cover the characteris-
tics and the therapeutic potential of EPCs, BM-MNCs and
recently identified CD31+ cells.
Endothelial progenitor cell
The EC population has been studied based on the idea that
these cells may play important roles in maintaining vascular
homeostasis and in the pathogenesis of a variety of disease.
Asahara and colleagues first demonstrated the presence of
BM-derived circulating progenitor cells or angioblasts in
human peripheral blood (hPB) (Asahara et al., 1997). These
progenitor cells displayed EC properties but also had the
potential to differentiate into ECs. These cells were referred to
as EPCs. This seminal publication manifested a novel concept
of post-natal vasculogenesis by postulating that, in addition
to vessel wall ECs, BM-derived circulating progenitor cells
participate in blood vessel growth, maintenance and repair.
This population was shown to be incorporated into the vas-
culature in adult animals and to induce new vessel formation
in ischaemic tissues (Asahara et al., 1999). The transplanta-
tion of EPCs into ischaemic tissues induced neovasculariza-
tion and helped regenerate ischaemic tissue damage (Kalka
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et al., 2000). Although this novel concept of post-natal vas-
culogenesis has been widely accepted, the precise identifica-
tion of genuine EPCs has been complicated by the lack of
specific markers and phenotype diversity. In addition, the
advance of technologies allowed to identify the role of EPCs
in disease pathogenesis (Bertolini et al., 2006; 2007; Dimme-
ler et al., 2008; Kawamoto and Losordo, 2008) besides a
normal component of the formed elements of circulating
blood (Schatteman et al., 2007).
Early EPC
Initially, CD34 or VEGF receptor (VEGFR)-2, which was
already applied in the haematopoietic stem or progenitor
cell isolation, was used to isolate circulating EPCs or putative
angioblasts from PB (Asahara et al., 1997; Shi et al., 1998;
Peichev et al., 2000). However, due to the lack of the specific
surface markers for identifying circulating EPCs, EPCs were
enriched by short-term culture of various BM cell fractions
in endothelial differentiation media. For example, CD133,
which is displayed on immature haematopoietic stem cells
(HSCs), was used for culture derivation of EPCs (Fernandez
Pujol et al., 2000). For therapeutic purposes, short-term
culture of MNCs was widely used for deriving EPCs. In this
case, entire MNCs were cultured for 4–7 days on vitronectin-
or fibronectin-coated dishes and adherent cells were used as
EPCs although these cells are not EPCs as a whole but EPC-
enriched cells (Asahara et al., 1997; 1999; Dimmeler and
Zeiher, 2000; Kalka et al., 2000; Dimmeler et al., 2001). Typi-
cally, a majority of these cultured cells displayed
endothelial-like characteristics represented by the uptake of
acetylated low-density lipoproteins and the binding of
lectins and expression of several EC-specific proteins
[VEGFR-2, Tie2, vascular endothelial (VE)-cadherin, von Wil-
lebrand factor, endothelial NOS (eNOS) and CD146] and
showed a low proliferation rate. However, other studies have
raised questions regarding the endothelial-like features of
these EPCs by showing that these cells also express
monocyte/macrophage markers such as CD45, CD14,
CD11b and CD11c (Schmeisser et al., 2001; Gulati et al.,
2003; Rehman et al., 2003; Ingram et al., 2005). More
recently, these cells were referred to as circulating angiogenic
cells (Gulati et al., 2003) as these EPCs rarely give rise to ECs
in vivo but contribute to vessel formation mainly through
their angiogenic effects. Alternative techniques have been
used to isolate cells similar to these EPCs, where whole
MNCs were seeded on fibronectin-coated plates. After 2
days, only non-adherent cells were collected for removal of
mature ECs and macrophages, and subsequently re-seeded
on fibronectin-coated plates. Colonies were generated after
5–9 days and named colony-forming unit-Hill or colony-
forming unit-ECs (Hill et al., 2003). However, the identity
and characteristics of these cells appear not to be similar to
aforementioned early EPCs.
EPCs contribute to vascular regeneration, in part, by
incorporating into the neovasculature and differentiating
into ECs (Asahara et al., 1997; 1999; Kocher et al., 2001).
Evidence also suggests that populations of cells containing
EPCs are inherently multipotent and may also include
smooth muscle progenitor cells (Wang et al., 2003). EPC dif-
ferentiation into cardiomyocytes and smooth muscle cells
has been reported in mouse (Yeh et al., 2003) and rat (Iwasaki
et al., 2006; Kawamoto et al., 2006) models of MI, and PB
EPCs mobilized by granulocyte-colony stimulating factor
(G-CSF) administration and myocardial ischaemia have been
shown to express cardiac-, muscle-, liver- and neural-lineage
markers (Kucia et al., 2004; Ratajczak et al., 2004). Most
reports have found little evidence of fusion between EPCs
and cells of other lineages (Koyanagi et al., 2005; Iwasaki
et al., 2006); however, results from one study indicated that
70% of newly formed cardiomyocytes in mice administered
human EPCs contained both human and mouse X chromo-
somes, suggesting that EPCs may transdifferentiate by fusing
with cells of a different lineage (Zhang et al., 2004). The
proportion of ECs displaying evidence of human–mouse cell
fusion was less than 3%. In fact, most recent studies have
suggested that although transdifferentiation of EPCs are pos-
sible, such phenomenon is not prevalent and may not under-
lie biologic effects derived from EPCs. In addition to their role
as a structural tissue component, EPCs express many factors
that contribute to tissue regeneration and preservation,
including the eNOS and inducible iNOS, which increase cir-
culation by dilating capillaries (Ii et al., 2005), and pro-
angiogenic or anti-apoptotic growth factors [e.g. VEGF,
hepatocyte growth factor (HGF), insulin-like growth factor 1
(IGF-1)] (Urbich et al., 2005). Growth factor release stimulates
the recruitment of additional EPCs to the ischaemic area
(Cho et al., 2007) and influences the proliferation, migration
and survival of both EPCs and pre-existing mature ECs
(Folkman, 1995). The therapeutic potential has been evalu-
ated in many studies. Cells were often administered systemi-
cally in early investigations, but more recent experiments
have tended to employ cell transplantation (i.e. injection
directly into the infarcted artery or ischaemic tissue) in an
effort to overcome the low rate of retention by systemically
administered cells. Transplantation of EPCs (Kalka et al.,
2000; Kawamoto et al., 2001; 2003; Kocher et al., 2001; Muro-
hara, 2001) augmented neovascularization in animal models
of acute myocardial ischaemia, and evidence of similar effects
in humans has also been reported (Assmus et al., 2002;
Stamm et al., 2003; Dobert et al., 2004).
Late EPC
Other types of EPCs have been discovered from circulating
MNCs, such as outgrowth ECs (Lin et al., 2000), late EPCs (Shi
et al., 1998) or endothelial colony-forming cells (ECFCs) as
these cells appear late (typically more than 2 weeks) in the
conventional EPC culture conditions. Although the culture
methods are somewhat variable, these cells essentially share
common characteristics in cell morphology (round), prolif-
eration rate (rapid) and surface marker expression (EC
markers only) (Ingram et al., 2004; 2005). Specifically, ECFCs
do not express haematopoietic (CD45) and monocytic
(CD14) markers but express most EC proteins. However, para-
crine effects were limited compared with early EPCs and their
vasculogenic effects were only demonstrated in a Matrigel™
plug assay (Ingram et al., 2004; Yoon et al., 2005a). Thus, their
EC generation capabilities and regenerative or therapeutic
effects on vasculature in ischaemic animal models need to be
further investigated. It is possible that these cells are primitive
circulating ECs or ECs sloughed off from vessels. The differ-
ence between ECFCs and mature ECs also remains to be
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determined. For therapeutic application, the clinically com-
patible culture systems need to be established.
Haematopoietic stem cells
HSCs are multipotent stem cells that give rise to all the
blood cell types such as the myeloid (monocytes and macro-
phages, neutrophils, basophils, eosinophils, erythrocytes,
megakaryocytes/platelets, dendritic cells) and lymphoid lin-
eages (T-cells, B-cells, NK-cells), and have the capacity for
self-renewal (Reya et al., 2001). In adult vertebrates, HSCs
originate from BM and occupy <1% of total BM cells. The
haematopoietic tissue contains cells with long-term and
short-term regeneration capacities and committed multipo-
tent, oligopotent and unipotent progenitors. HSCs constitute
1:10 000 of cells in myeloid tissue. A fraction of HSCs are also
found in circulating PB. HSCs are one of the best character-
ized stem cells and identified by a lack of markers that are
used for detection of lineage commitment (lin-) and the pres-
ence of combinations of the following markers: CD133,
CD34, CD38, CD90 (Thy1), CD105 and CD117 (C-kit) (Span-
grude et al., 1988; Baum et al., 1992; Seita and Weissman,
2010).
HSCs have been used for the treatment of haematologic
disease patients for more than three decades. The transplan-
tation of a single HSC can constitute all haematopoietic cells
in an organism and fulfil the criteria of every stem cell func-
tion. Due to their multipotency, in earlier studies, HSCs were
used to regenerate damaged myocardium (Orlic et al., 2001).
This study has shown that HSCs could generate new cardio-
myocytes, ECs and smooth muscle cells, and improve
post-MI cardiac function. Another versatile capacity of HSCs
has been reported with side population cells, which expel
Hoechst dye (Goodell et al., 1996). The differentiation poten-
tials of these cells into cardiomyocytes, ECs and vascular
smooth muscle cells were also demonstrated in an MI model
(Jackson et al., 2001). However, other studies have argued
that HSCs represented by lin-negative, sca1-positive and
c-kit-positive cells do not transdifferentiate into any cardio-
vascular cells in the infarcted heart after HSC transplantation
(Balsam et al., 2004; Murry et al., 2004). These studies were
performed in murine HSCs and no such experiments were
conducted with specific human HSCs other than CD34+ cells
and CD133+ cells that are enriched with human HSCs and
EPCs. Studies using human CD34+ cells (Yeh et al., 2003;
Kawamoto et al., 2006; Losordo et al., 2007; Wang et al.,
2010) or CD133+ cells (Leor et al., 2006; Schots et al., 2007;
Flores-Ramirez et al., 2010) have been reported to improve
post-MI cardiac function; however, the therapeutic mecha-
nism turned out to be non-transdifferentiation effects. As
CD34+ cells or CD133+ cells are present in low numbers in
circulation, the use of mobilizing cytokines such as G-CSF for
obtaining a large number of cells needed for clinical use
incurs high costs and risk to patients.
BM-mononuclear cells
BM-mononuclear cells (BM-MNCs) comprise a mixed popu-
lation of cells (e.g. haematopoietic cells, fibroblasts, osteob-
lasts, myogenic cells, endothelial-lineage cells) (Kamihata
et al., 2001). Transplantation of BM-MNCs (Fuchs et al., 2001;
Kamihata et al., 2001) augmented neovascularization in
animal models of acute myocardial ischaemia, and evidence
of similar effects in humans has also been reported (Strauer
et al., 2002; Tateishi-Yuyama et al., 2002; Perin et al., 2003;
Mocini et al., 2006). The monocyte/macrophage fraction of
BM-MNCs expresses important angiogenic growth factors
and cytokines [e.g. VEGF, basic fibroblast growth factor
(bFGF), angiopoietin-1 (Ang-1), IL-1b, TNF-a] and stimulates
angiogenesis (Leibovich et al., 1987; Giulian et al., 1988;
Kamihata et al., 2001). This cocktail of angiogenic factors
may also put forth potent paracrine effects that enhance the
proliferation, homing and differentiation of resident stem
cells (Toda et al., 2003).
The various effects exerted by the many cell types in the
BM-MNC population are not exclusively beneficial. Lym-
phocytes and monocytes/macrophages are the most preva-
lent MNCs and pro-inflammatory cytokines produced by
these cells including IL-1, IL-2, IL-6, IL-12, IFN- g, lympho-
toxin and TNFs (Mosmann, 1994; O’Garra and Murphy,
1996; Chandrasekar et al., 1999) may have a negative ino-
tropic effect in the myocardium. In addition, the high
number of inflammatory cells present in the MNC popula-
tion may accelerate myocardial damage after MI, and severe
haemorrhaging or inflammation caused by transplanted
MNCs could interfere with the long-term survival and differ-
entiation of the transplanted cells (Kawamoto et al., 2006).
Non-transdifferentiation therapeutic
effects of BM-derived cells
Despite the fact that BM-derived stem or progenitor cells have
emerged as a promising therapeutic modality, there have
been several controversies regarding therapeutic mechanisms
for ischaemic diseases. In particular, the plasticity or true
tissue generation capacity (transdifferentiation into cardio-
myocytes, smooth muscle cells and ECs) of BM-derived cells
has been widely debated (Balsam et al., 2004; Murry et al.,
2004; Ziegelhoeffer et al., 2004). Although therapeutic effects
are observed, it is now well accepted that the occurrence of
vasculogenesis and exogenous myogenesis in damaged
tissues are very low. Many recent studies suggested that the
paracrine mechanism could be a major mechanism to
mediate therapeutic effects in cardiovascular diseases. BM
cells release angiogenic factors such as VEGF, monoycyte
chemotactic protein-1 (MCP-1, also known as CCL2), FGF-2,
Ang-1 and Wnt (Kamihata et al., 2001; Fuchs et al., 2005;
Barcelos et al., 2009) and cultured early EPCs secrete HGF,
VEGF, G-CSF, IGF-1 and stromal derived factor-1 (SDF-1)
(Rehman et al., 2003; Urbich et al., 2005). Rehman et al.
(2003) quantified various growth factors released from cul-
tured early EPCs to the culture media over 72 h: VEGF (7601
 2611 pg), HGF (6912  1345 pg), G-CSF (8925  3255 pg)
and GM-CSF (492  453 pg) per 106 cells. Kinnaird et al. also
measured VEGF (375 pg·mg-1 protein), bFGF (2320 pg·mg-1),
placental growth factor (119 pg·mg-1) and MCP-1
(150 pg·mg-1) secreted from MSCs into the culture media for
24 h (Kinnaird et al., 2004). Urbich et al. also reported that
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cultured early EPCs released significantly higher amount of
pro-angiogenic factors VEGF and SDF-1, IGF-1 and HGF com-
pared to human umbilical vein endothelial cells determined
by ELISA of culture media (Urbich et al., 2005). One recent
study reported an important role of Wnt signalling in medi-
ating angiogenic effects of human fetal CD133+ cells on
ischaemic wounds (Barcelos et al., 2009). These growth
factors promote angiogenesis, protect against tissue apoptosis
or necrosis, and induce endogenous resident stem cell migra-
tion and proliferation through a paracrine response (Kinnaird
et al., 2004; Gnecchi et al., 2005; Urbich et al., 2005; Yoon
et al., 2005b; Tolar et al., 2007; Barcelos et al., 2009). Addi-
tionally, it is now known that these humoral effects are not
only attributed to implanted cells, but also to host tissues that
had received cell therapy (Tateno et al., 2006; Tolar et al.,
2007). However, the evidence of paracrine effects derived
from late EPCs or ECFCs is not clear. As a mechanism for
transdifferentiation, studies have claimed that fusion can be a
mechanism for transdifferentiation (Terada et al., 2002; Ying
et al., 2002). Although earlier reports emphasized the role of
fusion for transdifferentiation (Alvarez-Dolado et al., 2003;
Nygren et al., 2004), more recent studies have shown that
fusion is only partly or minimally responsible for the pheno-
typic changes of stem cells (Yoon et al., 2005b).
Haematopoietic CD31+ cells
Role of CD31 in vascular biology
CD31, also known as platelet endothelial cell adhesion
molecule-1, is a 130 kDa transmembrane protein consisting
of six extracellular immunoglobulin folds (Figure 1). In its
cytoplasmic domain, there are two immunoreceptor tyrosine-
based inhibitory motifs (ITIM) for interactions with signal-
ling molecules. CD31 is expressed on the cell surface of ECs
and haematopoietic cells such as monocytes, platelets, neu-
trophils, natural killer cells, megakaryocytes and some T cells.
CD31 mediates homotypic adhesion between adjacent ECs as
well as between ECs and leukocytes (Albelda et al., 1991; Xie
and Muller, 1993). A role of CD31 in migration through ECs
has also been reported for neutrophils and monocytes
(Muller et al., 1993), and subsequently for numerous other
cell types including natural killer cells (Berman et al., 1996),
haematopoietic progenitor cells (HPCs) (Voermans et al.,
2000) and certain subsets of lymphocytes (Zocchi et al., 1996;
Schenkel et al., 2004).
Role of CD31 in survival and angiogenesis
Cell–cell and cell–extracellular matrix interactions have been
shown to play pivotal roles in coordinating EC proliferation
and apoptosis required for proper blood vessel formation and
regression. There is growing evidence that CD31 could trans-
duce signals that suppress cell death. It has been proposed
that homophilic interactions of CD31 between ECs and
monocytes decrease apoptotic EC death (Noble et al., 1999).
This finding suggests that CD31 homophilic interactions
result in the transmission of pro-survival signals. In addition,
CD31 engagement has been reported to induce Akt, a serine/
threonine protein kinase, phosphorylation. CD31 itself has
also been involved during EC apoptosis by two pathways:
a metalloproteinase-dependent cleavage and a caspase-
mediated cleavage of the cytoplasmic tail (Ilan et al., 2001).
Given its abundant expression in ECs, CD31 has been
shown to be involved in the initial stabilization and forma-
tion of cell–cell contacts at lateral junctions of ECs, the main-
tenance of a vascular permeability barrier, modulation of cell
migration, transendothelial migration of monocytes and
neutrophils, and formation of blood vessels in angiogenesis
(Newman et al., 1990; Albelda et al., 1991; Muller et al., 1993;
DeLisser et al., 1997). Additionally, CD31 was found to form
a functional complex with VE-cadherin, b-catenin and
F-actin to control EC tube formation (Matsumura et al.,
1997). More recent data showed the involvement of CD31 in
the adhesion/signalling events necessary for the migration of
ECs and subsequent tube formation during angiogenesis,
independent of VE-cadherin (Cao et al., 2002).
Identification of specialized
multimodal angio-vasculogenic cells:
role of haematopoietic CD31+ cells
As the major mechanisms underlying therapeutic effects for
BM-derived stem or progenitor cells turned out to be humoral
effects (Kinnaird et al., 2004; Gnecchi et al., 2005; Uemura
et al., 2006; Cho et al., 2007), identifying such cells could lead
to the development of next generation cell therapy. There-
fore, recent studies explored whether or not cells enriched
with humoral activities can be found from BM and/or PB
(Kim et al., 2010a,c). At the same time, these studies sought to
use a surface marker to isolate these cells. By avoiding cell
culture, direct isolation using a surface marker can circum-
vent deleterious effects associated with the use of animal
serum and extra costs related to cell cultivation. Since CD31
is a well-known EC marker, CD31+ cells may meet such end.
In fact, these two studies demonstrated more broadly that
BM-derived CD31+ cells have multimodal effects including
angiogenic, vasculogenic, higher adhesion and almost exclu-
sive haematopoietic stem/progenitor cell activities (Figure 2).
Figure 1
The structure of CD31. CD31 is a 130-kD type I transmembrane
glycoprotein and a member of Ig gene superfamily.
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Angiogenic activities
This study first looked at the angiogenic activities of the
CD31+ cells. Genome-wide gene expression studies followed
by gene set enrichment analysis and hierarchical cluster
analysis with mouse BM (mBM), human BM (hBM) and hPB
showed that angiogenic genes were globally up-regualted in
CD31+ cells compared with CD31- cells (Kim et al., 2010a,c).
The angiogenic genes were significantly enriched in the
CD31+ cells compared with the corresponding CD31- cells.
mBM-CD31+ cells expressed very high levels of Ang-1 and
GATA2 compared with the CD31- cells, whereas hBM-CD31+
cells expressed higher levels of heparin-binding EGF-like
growth factor (HBEGF) and IL-8 than hBM-CD31- cells. Ang-1
is a well-known angiogenic growth factor (Jones et al., 2001;
Cho et al., 2004) and GATA2 is a transcription factor, which,
when activated, increases angiogenesis (Mammoto et al.,
2009). HBEGF is involved in the recruitment of vascular
smooth muscle cells (Iivanainen et al., 2003) and IL-8 is a
macrophage-derived mediator of angiogenesis (Koch et al.,
1992). Neuropilin-1 (NRP1) is the most highly expressed ang-
iogenic gene in hPB-CD31+ cells compared with hPB-CD31-
cells. NRP1 is required for vascular development and medi-
ates VEGF-dependent angiogenesis (Lee et al., 2002).
Vasculogenic properties
One important question is to address whether any haemat-
opoietic cells contribute to true EC generation and to deter-
mine the identity of such cells. Prior studies from other
investigators and ours have provided evidence that there is
quite a reasonable possibility that certain BM-derived cell
populations can give rise to ECs (Shi et al., 1998; Lyden et al.,
2001; Orlic et al., 2001). However, some earlier studies have
strongly argued against these phenomena (Balsam et al.,
2004; Ziegelhoeffer et al., 2004; O’Neill et al., 2005). Repre-
sentative studies that refuted EC generation by haematopoi-
etic cells used MI models (Balsam et al., 2004; Murry et al.,
2004) to prove the vasculogenic effects. However, an MI
model allows very minimal engraftment of any cells, not only
BM-derived cells. Studies have shown that the engraftment
rate of embryonic stem cells differentiated into cardiomyo-
genic lineages, or cardiac stem or progenitor cells are also very
minimal in an MI model (Smith et al., 2007; Smits et al.,
2009; Tang et al., 2010). The constant motion of the heart,
ongoing inflammation in acute stages of infarction, and little
oxygen and nutrients in the acutely ischaemic heart put the
implanted cells into an environment too harsh for engraft-
ment and survival. Tight junctions between cardiomyocytes
could be another hurdle for engraftment of externally
injected cells. Furthermore, most studies refute the transdif-
ferentiation potential based on extremely low rate of cardio-
myocyte transdifferentiation from BM cells rather than ECs.
In fact, one study by the same author showed that EC
transdifferentiation is not infrequent in transplanted heart
samples (Virag and Murry, 2003). Thus, it appears the
transdifferentiation potential of BM cells into ECs should be
re-evaluated. Amid such controversy, independent studies
have shown such potential that if appropriate BM-derived
cells are injected into more permissive models, they can give
rise to ECs. Particularly, studies using tumour models have
clearly demonstrated transdifferentiation potential of BM
cells into ECs (Nolan et al., 2007; Gao et al., 2008). Together,
these studies suggest that the generation of ECs from BM or
PB cells may not only depend on the cell types but also the
experimental models or host environment.
The vasculogenic effects of CD31+ cells have been inves-
tigated in recent studies (Kim et al., 2010a,c). In vitro assays
showed that mBM-, hBM- and hPB-CD31+ cells generated a
markedly high number of EPCs under culture, compared with
the CD31- cells. Results from an in vitro EC differentiation
assay using hPB-CD31+ cells showed expression of EC-specific
markers, such as von Willebrand factor, VEGFR-2,
VE-cadherin and CD31, in CD31+ cells. Intriguing morpho-
logical changes of the hPB-CD31+ cells were observed in this
culture. Under endothelial differentiation conditions, hPB-
CD31+ cells formed cellular aggregates on day 7, which sub-
sequently underwent tubular structural changes within the
round cell cluster by day 10 followed by formation of com-
plete linear tubular structures that mimicked in vivo vasculo-
genesis. These tubular structures stained positive for lectin
and took up acetylated human low-density lipoprotein, indi-
cating EC characteristics. Further evidence of vasculogenesis
was shown by in vivo animal studies. A mouse model of
hindlimb ischaemia was used for testing vasculogenic activi-
ties of CD31+ cells (Kim et al., 2010a,c). Given the controversy
of transdifferentiation potential of BM cells (Lyden et al.,
2001; Rehman et al., 2003; Balsam et al., 2004; Ziegelhoeffer
et al., 2004; Nolan et al., 2007; Gao et al., 2008), a series of
rigorous methods and criteria were used to confirm differen-
tiation. Confocal microscopy with 3D reconstruction of mul-
tiple images was used as a first step. This technique clearly
demonstrated that a fraction of CD31+ cells was co-localized
with ECs within the vascular structure even up to 8 weeks
after. In addition, flow cytometric analysis of enzymatically
digested hindlimb tissues showed that up to 4% of the ECs in
the ischaemic tissues was derived from transplanted mBM- or
hPB-CD31+ cells. Fluorescent in situ hybridization of the
digested tissues further confirmed the contribution of hPB-
CD31+ cells into ECs (Kim et al., 2010c). No other studies
adopted all of these technologies to prove transdifferentia-
tion of haematopoietic cells. These data clearly indicate that
Figure 2
Pleiotropic effects of BM-derived haematopoietic CD31+ cells. Various
beneficial effects of CD31+ cells on therapeutic neovascularization
and tissue regeneration are summarized.
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functional ECs can be derived from directly injected CD31+
cells in the ischaemic tissue.
Higher adhesion and engraftment potential
Studies have shown that engraftment of transplanted neona-
tal cardiomyocytes is less than 25% within 24 h of MI in
animal models (Muller-Ehmsen et al., 2002) and 5% after 1 h
post-injection of CD34+ cells in human patients with MI
(Musialek et al., 2011). Another study demonstrated that a
majority of cultured early EPCs injected directly into the
myocardium post-MI disappeared within a week (Cho et al.,
2007). This low engraftment of injected cells is a major
problem in order to enhance therapeutic effects of cell
therapy because stable engraftment and survival of implanted
cells should be a prerequisite for ‘cell’ therapy. One recent
study suggested an association between durable engraftment
of the transplanted EPCs and maintenance of functional
improvement in experimental diabetic neuropathy (Jeong
et al., 2009). When cultured, early EPCs were intramuscularly
transplanted along the nerve, they engrafted into the diabetic
nerve along the vasa nervorum for more than 12 weeks and
improved neural function for more than 8 weeks (Jeong et al.,
2009).
Cells that successfully adhere to the extracellular matrix
have a higher chance of survival by avoiding anoikis (apop-
tosis caused by lack of adhesion to extracellular matrix). This
adhesion capacity may play an important role in cell survival,
particularly in the ischaemic environment. CD31 was origi-
nally discovered as an adhesion molecule between cells (Xie
and Muller, 1993; Zocchi and Poggi, 1993), and it has been
shown to mediate cell–cell adhesion mainly through
homophilic interactions between CD31-expressing cells
(Woodfin et al., 2007). Genome-wide gene expression data
showed a high expression of genes related to adhesion, trans-
membrane structure, chemokine production and reception,
and extracellular matrix in hPB-CD31+ cells (Kim et al.,
2010c). Cell adhesion assays further demonstrated that
CD31+ cells have a higher adhesion capacity to various extra-
cellular matrix proteins such as collagen, laminin, vitronectin
and fibronectins than CD31- cells (Kim et al., 2010a,c). In
fact, the confocal microscopic data and FACS analysis for
digested tissues verified higher engraftment of mBM-CD31+
cells compared with mBM-CD31- cells in cell transplantation
studies with a hindlimb ischaemia model. CXCR4/ SDF-1 is a
well-known signalling axis to mediate cell engraftment and
migration. However, the expression of CXCR4 was not differ-
ent between CD31+ cells and CD31- cells, suggesting that the
higher engraftment of CD31+ cells does not depend on this
pathway. On the other hand, the CD31 molecule itself and
other adhesion molecules ICAM4 and integrin a which were
more highly expressed in CD31+ cells than CD31- cells could
have contributed to the higher engraftment of CD31+ cells.
The higher engraftment of CD31+ cells is likely to augment
the angiogenic and vasculogenic ability of mBM- and hPB-
CD31+ cells (Kim et al., 2010a,c). CD31 is the first marker used
to isolate a BM cell subpopulation that has higher adhesion
and engraftment potential.
Together, BM-derived CD31+ cells exert therapeutic effects
mainly through non-transdifferentiation humoral effects. By
avoiding cumbersome BM biopsy or cell mobilization used
for isolation of other progenitor cells such as CD34+ or
CD133+ cells, CD31+ cell therapy will become a promising
option for treating patients with advanced ischaemic cardio-
vascular diseases.
Enriched HSCs and HPCs
Gene expression studies have shown that the levels of hae-
matopoietic stem and progenitor cell genes were higher in
mBM-CD31+ cells and hBM-CD31+ cells than mBM-CD31-
cells and hBM-CD31- cells respectively (Kim et al., 2010a),
supporting the notion that haematopoietic stem and pro-
genitor cells are enriched in the CD31+ cells. FACS analysis
confirmed that more than 90% of HSCs, multipotent
progenitor cells, common lymphoid progenitor cells and
common myeloid progenitor cells in mBM express CD31
(Kim et al., 2010a). In vitro colony-forming assays and in vivo
BM cell transplantation experiments further support that
haematopoietic stem and progenitor cells are almost exclu-
sively included in mBM-CD31+ cells (Kim et al., 2010a). Simi-
larly, in hBM, CD31 was expressed in 99.8% of CD34+CD133+
and 89% of CD34+CD133-, indicating that HSCs and most
HPCs express CD31 (Kim et al., 2010a). In vitro haematopoi-
etic colony-forming assays revealed that clonogenic HPCs are
enriched in hPB-CD31+ cells (Kim et al., 2010c). These studies
indicate that HSCs and HPCs are almost exclusively included
in the CD31+ cell fraction.
CD34+ cells are effective for improving ischaemic cardio-
vascular diseases in animal models (Kawamoto et al., 2003)
and human patients (Losordo et al., 2007; Kawamoto et al.,
2009). Given that HSCs/EPCs that are heavily enriched in the
CD34+ cell fraction are almost exclusively present in the
CD31+ population, and that HSCs/EPCs have been reported
to be instrumental for therapeutic neovascularization in
ischaemic cardiovascular diseases, it is questionable whether
HSC populations included in CD31+ cells are responsible for
ischaemic cardiovascular repair. When this population (hBM-
CD34-CD31+ cells) was compared with hBM-CD34+ cells,
therapeutic effects between these two groups were similar in
improving mouse limb ischaemia, suggesting that non-HSC
populations among the CD31+ cell fraction play important
roles in therapeutic neovascularization.
Clinical application
One major advantage of CD31+ cells over CD34+ or CD133+
cells is their prevalence in circulating blood. Approximately
30–35% of total MNCs of hPB are CD31+. For instance, if 60
million CD31+ cells are needed for transplantation, only
100 mL of blood is needed (Kang et al., 2004; Kawamoto
et al., 2009). Thus, there is no need to use mobilizing agents,
such as G-CSF, for collecting CD31+ cells (Kawamoto et al.,
2009; Losordo et al., 2011). This leads to the reduction in cost
of cell therapy, simplification of treatment procedures and
removal of potential adverse effects associated with mobiliz-
ing agents. Another advantage of CD31+ cells over the cul-
tured EPCs or MSCs is the avoidance of cell culture. The
major drawback of cultured cells for clinical use is culture-
associated side effects. Current EPC or MSC expansion proto-
cols utilize media containing fetal bovine serum. This use of
xenogeneic serum can pose a risk such as disease transmission
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through viral, prion, and zoonose contamination or immu-
nizing effects. One early study reported that patients receiv-
ing repeated MSC transplantation developed anti-fetal
bovine serum antibodies and elicited inflammatory and
immunological reactions, provoking influencing the thera-
peutic results (Horwitz et al., 2002). Another potential benefit
over uncultured BM-derived MNCs or unfractionated cells is
the removal of unnecessary cells that may induce adverse
effects such as calcification (Yoon et al., 2004) or aggravation
of ischaemia (Miyamoto et al., 2006). In the studies using
CD31+ cells, no adverse effects were observed (Kim et al.,
2010a,c). Recent studies suggested that BM-MNCs (Iso et al.,
2010) or G-CSF-mobilized PB-MNCs (Horie et al., 2010) are
effective in the treatment of patients with critical limb ischae-
mia. When we compared hBM-MNCs with hBM-CD31+ cells
in a mouse model of hindlimb ischaemia, the therapeutic
efficacy of CD31+ cells was superior to that of BM-MNCs.
Thus, CD31+ cell selection by removing nonangiogenic and
highly inflammatory cells included in the CD31- cell fraction
appears to have higher therapeutic effects and less potential
toxicity.
Future perspective
One barrier to the use of EPCs, particularly the uncultured
EPCs in cardiovascular regeneration, is the low number of
cells to be obtained from the PB. In addition, the number
and/or function of EPCs are reported to be reduced in
patients with advanced age (Heiss et al., 2005), diabetes (Ii
et al., 2006), hypercholesterolaemia (Vasa et al., 2001) or
hypertension (Vasa et al., 2001; Imanishi et al., 2005), and in
patients who smoke (Kondo et al., 2004; Michaud et al.,
2006). Thus, the clinical success of EPC therapy may depend
on the development of efficient methods to increase the
number and/or potency of EPCs.
To identify more angiogenic and/or vasculogenic cells,
further experimental investigation is required. As CD31+ cells
are a heterogeneous cell population that includes T and B
lymphocytes and myelomonocytic cells, more restricted ang-
iogenic or vasculogenic cells can be identified by using addi-
tional markers. The addition of other markers will help
narrow down the identification of more specialized cells to
possess higher angiogenic and vasculogenic potency. Mecha-
nistically, the role of CD31 itself in mediating neovasculari-
zation in the ischaemic tissues needs to be determined.
Although CD31 knockout mice display a grossly normal phe-
notype (Thompson et al., 2001), studies with tissue- and
time-specific conditional deletion or overexpression of CD31
genes are required to elucidate this role.
As experimental proof has been provided, clinical trials
with CD31+ cells should follow. The first target could be the
patients with critical limb ischaemia or non-healing wounds.
There are a number of reports that the efficacy of myocardial
repair or regeneration with BM-derived cells may be minimal
or modest. However, studies with unselected BM or PB-MNCs
for treating peripheral vascular obstructive disease has shown
to be effective (Al Mheid and Quyyumi, 2008). In addition, a
recent presentation showed that CD34+ cells are effective in
the treatment of critical limb ischaemia patients (Losordo
et al., 2010). Peripheral tissues have more room for cell
engraftment and present a less hostile environment for cell
survival. As such, critical limb ischaemia could be a good
initial target for cell therapy with CD31+ cells. A recent dia-
betic neuropathy study also indicated that the host environ-
ment is a more important factor in determining engraftment
and survival (Jeong et al., 2009; Kim et al., 2009). Upon
success with critical ischaemia, this cell therapy can be
expanded to the treatment of other ischaemic cardiovascular
diseases including MI, stroke and diabetic neuropathy.
A decade of experience with BM cell therapy for cardio-
vascular diseases has yielded novel insight into the underly-
ing mechanisms. Important discoveries include the major
role of the humoral and paracrine mechanisms, the impor-
tance of the host environment in cell engraftment and thera-
peutic effects, and the advantages of selected cells. Based on
these new findings, we believe that now is the time to rethink
the therapeutic usefulness of currently used cell types. As far
as therapeutic effects are not heavily dependent upon tissue
generation from transplanted cells, we may not need to
adhere to using stem or progenitor cells which only exist in
low number and requires special measures for isolation, but
to focus on identifying and applying specialized angiogenic
and/or vasculogenic effector cells for therapy. Furthermore,
tailored therapy according to the type of target disease should
be considered. Additionally, engineering of cells with bioma-
terials is required to improve cell function, delivery and
retention.
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